Iradimed CORP (IRMD) — SEC Filings

Overview

Iradimed CORP (IRMD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 3, 2025: IRADIMED CORP (IRMD) reported robust financial performance for the nine months ended September 30, 2025, with revenue increasing by 13.5% to $61,122,101 from $53,852,954 in the prior year period. Net income also saw a significant rise of 13.8%, reaching $16,038,042 compared to $14,087,248 in the sam

Sentiment Summary

Across 29 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 26 neutral, 1 mixed. The dominant filing sentiment for Iradimed CORP is neutral.

Filing Type Overview

Iradimed CORP (IRMD) has filed 10 8-K, 6 10-Q, 1 10-K/A, 2 DEF 14A, 2 10-K, 4 SC 13G/A, 3 SC 13G, 1 DEFA14A with the SEC between Feb 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (29)

• 8-K Filing — 8-K · Dec 8, 2025
• IRADIMED's Q3 Revenue Jumps 13.5%, Net Income Up 13.8% — 10-Q · Nov 3, 2025 Risk: medium
  IRADIMED CORP (IRMD) reported robust financial performance for the nine months ended September 30, 2025, with revenue increasing by 13.5% to $61,122,101 from $5
• IRADIMED Amends 10-K for Certification Omission; 2024 Revenue Hits $73.2M — 10-K/A · Sep 3, 2025 Risk: low
  IRADIMED CORP (IRMD) filed a 10-K/A on September 3, 2025, to correct an omission of Section 906 certifications in Exhibit 32.1 from its original 10-K filed on M
• IRADIMED CORP Files 8-K: Board & Compensation Updates — 8-K · Sep 2, 2025 Risk: low
  On August 27, 2025, IRADIMED CORP filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing also inclu
• IRADIMED Posts Mixed Q2: US Growth Offsets International Dip — 10-Q · Aug 1, 2025 Risk: medium
  IRADIMED CORP (IRMD) reported a mixed financial performance for the quarter ended June 30, 2025. Revenue from U.S. operations for the three months ended June 30
• IRADIMED CORP Files 8-K on Security Holder Vote Matters — 8-K · Jun 23, 2025 Risk: low
  On June 23, 2025, IRADIMED CORP filed an 8-K report indicating a submission of matters to a vote of security holders. The filing does not contain specific detai
• IRADIMED CORP Files 8-K with Financial Statements — 8-K · May 29, 2025 Risk: low
  On May 29, 2025, IRADIMED CORP filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update or disclosure r
• IRadimed Corp. Files Q1 2025 10-Q — 10-Q · May 5, 2025 Risk: low
  IRadimed Corp. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 20
• IRADIMED CORP Files 2025 Proxy Statement — DEF 14A · Apr 30, 2025 Risk: low
  IRADIMED CORP filed a DEF 14A proxy statement on April 30, 2025, for the fiscal year ending December 31, 2024. The filing pertains to the company's annual meeti
• Iradimed Corp. Files 2024 Annual Report — 10-K · Mar 6, 2025 Risk: low
  Iradimed Corp. filed its 10-K for the fiscal year ending December 31, 2024, detailing its financial performance and business operations. The company, incorporat
• IRADIMED CORP Files 8-K on Financials — 8-K · Feb 13, 2025 Risk: low
  On February 13, 2025, IRADIMED CORP filed an 8-K report. The filing pertains to the company's results of operations and financial condition, as well as financia
• IRADIMED CORP Files 8-K on Financials — 8-K · Jan 10, 2025 Risk: low
  On January 10, 2025, IRADIMED CORPORATION filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as wel
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G Filing — SC 13G · Nov 8, 2024
• IRadimed Corp. Assets Stable at $126.7M — 10-Q · Oct 31, 2024 Risk: low
  IRadimed Corp. reported total assets of $126.7 million as of September 30, 2024, a slight increase from $126.6 million at the end of fiscal year 2023. The compa
• SC 13G Filing — SC 13G · Oct 22, 2024
• Iradimed Corp. Files Q2 2024 10-Q — 10-Q · Aug 1, 2024 Risk: low
  Iradimed Corp. reported its Q2 2024 financial results for the period ending June 30, 2024. The company's financial statements show changes in retained earnings
• IRADIMED CORP Files 8-K on Security Holder Vote — 8-K · Jun 20, 2024 Risk: low
  On June 20, 2024, IRADIMED CORP filed an 8-K report indicating that matters were submitted to a vote of security holders. The filing does not contain details on
• IRADIMED CORP Faces Nasdaq Listing Scrutiny — 8-K · Jun 7, 2024 Risk: medium
  On June 5, 2024, IRADIMED CORP filed an 8-K report indicating a potential delisting or failure to meet continued listing standards. The company is addressing is
• IRADIMED CORP Files 8-K for Material Definitive Agreement — 8-K · Jun 3, 2024 Risk: medium
  On May 29, 2024, IRADIMED CORP entered into a material definitive agreement. The filing also includes financial statements and exhibits related to this agreemen
• Iradimed Corp. Files Definitive Proxy Materials — DEFA14A · May 3, 2024 Risk: low
  Iradimed Corp. is filing a Definitive Additional Materials proxy statement on May 3, 2024. This filing is related to the company's proxy materials and does not
• IRADIMED CORP Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 2, 2024 Risk: low
  IRADIMED CORP (IRMD) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. IRADIMED CORP filed a 10-Q report for the period ending March 31, 2024. The fi
• IRADIMED CORPORATION Schedules 2024 Annual Meeting of Stockholders — DEF 14A · Apr 29, 2024 Risk: low
  IRADIMED CORP (IRMD) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Iradimed Corporation will hold its 2024 Annual Meeting of Stockholders on
• IRADIMED CORP Files 10-K for Fiscal Year Ended December 31, 2023 — 10-K · Mar 1, 2024 Risk: low
  IRADIMED CORP (IRMD) filed a Annual Report (10-K) with the SEC on March 1, 2024. IRADIMED CORP filed its annual 10-K report for the fiscal year ending December
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Nine Ten Capital Cuts IRMD Stake to 7.0%, Holding 799,366 Shares — SC 13G/A · Feb 12, 2024 Risk: medium
  Nine Ten Capital Management LLC, a Chicago-based investment firm, filed an amended Schedule 13G/A on February 12, 2024, disclosing its beneficial ownership in I
• BlackRock Discloses Passive Stake in IRADIMED CORP — SC 13G · Feb 9, 2024 Risk: low
  BlackRock Inc., a major investment firm, filed an SC 13G on February 9, 2024, disclosing its ownership of IRADIMED CORP's Class A Common Stock as of December 31
• IRADIMED Files 8-K on Financial Results, Operations — 8-K · Feb 8, 2024 Risk: medium
  IRADIMED CORPORATION filed an 8-K on February 8, 2024, to announce its results of operations and financial condition. This filing, under Items 2.02 and 9.01, in
• Soleus Capital Amends IRADIMED Stake, Signals Continued Interest — SC 13G/A · Feb 2, 2024
  Soleus Capital Master Fund, L.P. filed an amended Schedule 13G/A on February 2, 2024, indicating their ownership of IRADIMED CORPORATION (IRMD) common stock as

Risk Profile

Risk Assessment: Of IRMD's 23 recent filings, 0 were flagged as high-risk, 6 as medium-risk, and 17 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Iradimed CORP's most recent 10-Q filing (Nov 3, 2025):

• Revenue: $61,122,101
• Net Income: $16,038,042
• EPS: $0.43
• Debt-to-Equity: 0.17
• Cash Position: $56,526,151
• Operating Margin: 31.2%
• Total Assets: $114,721,779
• Total Debt: $16,369,808

Key Executives

• Roger Susi

Industry Context

Iradimed operates in the medical device industry, specifically focusing on non-invasive monitoring technologies. This sector is characterized by stringent regulatory oversight, particularly from the FDA, and a constant need for innovation to meet evolving healthcare demands. Competition can be intense, with established players and emerging companies vying for market share. The industry also faces supply chain complexities and the need for robust distribution networks.

Top Tags

corporate-governance (5) · financials (4) · Medical Devices (3) · Healthcare Technology (3) · 10-Q (3) · institutional-ownership (3) · MRI Compatible (2) · SEC Filing (2) · Financial Performance (2) · executive-compensation (2)

Key Numbers

• Revenue: $61.1M — Increased by 13.5% for the nine months ended September 30, 2025, from $53.9M in 2024.
• Net Income: $16.0M — Increased by 13.8% for the nine months ended September 30, 2025, from $14.1M in 2024.
• Cash and Cash Equivalents: $56.5M — Increased from $52.2M at December 31, 2024, demonstrating strong liquidity.
• Property and Equipment, Net: $23.8M — Increased significantly from $16.8M at December 31, 2024, indicating capital investment.
• Diluted EPS (Q3 2025): $0.43 — Increased from $0.40 in Q3 2024, showing improved profitability per share.
• Shares Outstanding: 12,721,156 — As of October 31, 2025, reflecting stable share count.
• Revenue Growth: 13.5% — Year-over-year growth for the nine months ended September 30, 2025.
• Net Income Growth: 13.8% — Year-over-year growth for the nine months ended September 30, 2025.
• Net Cash Provided by Operating Activities: $19.0M — Slight decrease from $19.6M in the prior year, but still substantial.
• Net Cash Used in Investing Activities: $8.0M — Increased from $5.8M in the prior year, reflecting higher capital expenditures.
• Income from operations: $22.0M — IRADIMED's income from operations for fiscal year 2024
• Operating profit margin: 30% — IRADIMED's operating profit margin for fiscal year 2024
• Aggregate market value of shares held by non-affiliates: $349,253,009 — As of June 30, 2024
• Shares outstanding of common stock: 12,715,072 — As of February 28, 2025
• MRI compatible IV infusion pump systems sold: 7,832 — As of December 31, 2024

Forward-Looking Statements

• {"claim":"Iradimed Corp's stock price may experience downward pressure in the short term.","entity":"IRMD","targetDate":"3 months","confidence":"medium"}
• {"claim":"Other institutional investors might re-evaluate their positions in Iradimed Corp.","entity":"IRMD","targetDate":"6 months","confidence":"medium"}
• {"claim":"IRADIMED's stock price will react significantly to the detailed financial results once they are fully disclosed.","entity":"IRADIMED CORPORATION","targetDate":"within 1 week of full disclosure","confidence":"high"}
• {"claim":"Analysts will issue updated ratings or price targets for IRADIMED based on the financial performance reported.","entity":"IRADIMED CORPORATION","targetDate":"within 2 weeks of full disclosure","confidence":"medium"}

Related Companies

PHG · MDT

Frequently Asked Questions